Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.0920
+0.0070 (8.24%)
Aug 1, 2025, 10:28 AM AEST
Invex Therapeutics Company Description
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial.
The company was incorporated in 2019 and is based in Perth, Australia.
Contact Details
Address: 38 Rowland Street Perth, 6008 Australia | |
| Phone | 61 8 6382 0137 |
| Website | invextherapeutics.com |
Stock Details
| Ticker Symbol | IXC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000048621 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Narelle Warren B.Com, B.Com., L.L.B., LLB | Chief Financial Officer and Company Secretary |
| Dr. Thomas Duthy M.B.A., Ph.D. | Executive Director |